172 related articles for article (PubMed ID: 35523073)
1. PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. A molecular imaging study.
Seki T; Saida Y; Kishimoto S; Lee J; Otowa Y; Yamamoto K; Chandramouli GV; Devasahayam N; Mitchell JB; Krishna MC; Brender JR
Neoplasia; 2022 Aug; 30():100793. PubMed ID: 35523073
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironment.
Kultti A; Zhao C; Singha NC; Zimmerman S; Osgood RJ; Symons R; Jiang P; Li X; Thompson CB; Infante JR; Jacobetz MA; Tuveson DA; Frost GI; Shepard HM; Huang Z
Biomed Res Int; 2014; 2014():817613. PubMed ID: 25147816
[TBL] [Abstract][Full Text] [Related]
3. PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models.
Morosi L; Meroni M; Ubezio P; Fuso Nerini I; Minoli L; Porcu L; Panini N; Colombo M; Blouw B; Kang DW; Davoli E; Zucchetti M; D'Incalci M; Frapolli R
J Exp Clin Cancer Res; 2021 Sep; 40(1):286. PubMed ID: 34507591
[TBL] [Abstract][Full Text] [Related]
4. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.
Jacobetz MA; Chan DS; Neesse A; Bapiro TE; Cook N; Frese KK; Feig C; Nakagawa T; Caldwell ME; Zecchini HI; Lolkema MP; Jiang P; Kultti A; Thompson CB; Maneval DC; Jodrell DI; Frost GI; Shepard HM; Skepper JN; Tuveson DA
Gut; 2013 Jan; 62(1):112-20. PubMed ID: 22466618
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20).
Wong KM; Horton KJ; Coveler AL; Hingorani SR; Harris WP
Curr Oncol Rep; 2017 Jul; 19(7):47. PubMed ID: 28589527
[TBL] [Abstract][Full Text] [Related]
6. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models.
Thompson CB; Shepard HM; O'Connor PM; Kadhim S; Jiang P; Osgood RJ; Bookbinder LH; Li X; Sugarman BJ; Connor RJ; Nadjsombati S; Frost GI
Mol Cancer Ther; 2010 Nov; 9(11):3052-64. PubMed ID: 20978165
[TBL] [Abstract][Full Text] [Related]
7. Predicting Gemcitabine Delivery by
Russell J; Grkovski M; O'Donoghue IJ; Kalidindi TM; Pillarsetty N; Burnazi EM; Kulick A; Bahr A; Chang Q; LeKaye HC; de Stanchina E; Yu KH; Humm JL
J Nucl Med; 2021 Feb; 62(2):195-200. PubMed ID: 32646874
[No Abstract] [Full Text] [Related]
8. Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy.
Blair AB; Wang J; Davelaar J; Baker A; Li K; Niu N; Wang J; Shao Y; Funes V; Li P; Pachter JA; Maneval DC; Dezem F; Plummer J; Chan KS; Gong J; Hendifar AE; Pandol SJ; Burkhart R; Zhang Y; Zheng L; Osipov A
Gastroenterology; 2022 Nov; 163(5):1267-1280.e7. PubMed ID: 35718227
[TBL] [Abstract][Full Text] [Related]
9. Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression.
Li X; Shepard HM; Cowell JA; Zhao C; Osgood RJ; Rosengren S; Blouw B; Garrovillo SA; Pagel MD; Whatcott CJ; Han H; Von Hoff DD; Taverna DM; LaBarre MJ; Maneval DC; Thompson CB
Clin Cancer Res; 2018 Oct; 24(19):4798-4807. PubMed ID: 30084839
[No Abstract] [Full Text] [Related]
10. Magnetic resonance imaging of tumor response to stroma-modifying pegvorhyaluronidase alpha (PEGPH20) therapy in early-phase clinical trials.
Arias-Lorza AM; Costello JR; Hingorani SR; Von Hoff DD; Korn RL; Raghunand N
Sci Rep; 2024 May; 14(1):11570. PubMed ID: 38773189
[TBL] [Abstract][Full Text] [Related]
11. Depolymerization of hyaluronan using PEGylated human recombinant hyaluronidase promotes nanoparticle tumor penetration.
Brundel DH; Feeney OM; Nowell CJ; Suys EJ; Gracia G; Kaminskas LM; McIntosh MM; Kang DW; Porter CJ
Nanomedicine (Lond); 2021 Feb; 16(4):275-292. PubMed ID: 33560142
[No Abstract] [Full Text] [Related]
12. Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors.
Manuel ER; Chen J; D'Apuzzo M; Lampa MG; Kaltcheva TI; Thompson CB; Ludwig T; Chung V; Diamond DJ
Cancer Immunol Res; 2015 Sep; 3(9):1096-107. PubMed ID: 26134178
[TBL] [Abstract][Full Text] [Related]
13. Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma.
Cao J; Pickup S; Clendenin C; Blouw B; Choi H; Kang D; Rosen M; O'Dwyer PJ; Zhou R
Clin Cancer Res; 2019 Apr; 25(7):2314-2322. PubMed ID: 30587546
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.
Infante JR; Korn RL; Rosen LS; LoRusso P; Dychter SS; Zhu J; Maneval DC; Jiang P; Shepard HM; Frost G; Von Hoff DD; Borad MJ; Ramanathan RK
Br J Cancer; 2018 Jan; 118(2):153-161. PubMed ID: 28949957
[TBL] [Abstract][Full Text] [Related]
15. Investigating the contribution of hyaluronan to the breast tumour microenvironment using multiparametric MRI and MR elastography.
Reeves EL; Li J; Zormpas-Petridis K; Boult JKR; Sullivan J; Cummings C; Blouw B; Kang D; Sinkus R; Bamber JC; Jamin Y; Robinson SP
Mol Oncol; 2023 Jun; 17(6):1076-1092. PubMed ID: 37081807
[TBL] [Abstract][Full Text] [Related]
16. Disruption of Hyaluronic Acid in Skeletal Muscle Induces Decreased Voluntary Activity via Chemosensitive Muscle Afferent Sensitization in Male Mice.
Queme LF; J Dourson A; Hofmann MC; Butterfield A; Paladini RD; Jankowski MP
eNeuro; 2022; 9(2):. PubMed ID: 35387844
[TBL] [Abstract][Full Text] [Related]
17. CD44 contributes to hyaluronan-mediated insulin resistance in skeletal muscle of high-fat-fed C57BL/6 mice.
Hasib A; Hennayake CK; Bracy DP; Bugler-Lamb AR; Lantier L; Khan F; Ashford MLJ; McCrimmon RJ; Wasserman DH; Kang L
Am J Physiol Endocrinol Metab; 2019 Dec; 317(6):E973-E983. PubMed ID: 31550181
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronan accumulates with high-fat feeding and contributes to insulin resistance.
Kang L; Lantier L; Kennedy A; Bonner JS; Mayes WH; Bracy DP; Bookbinder LH; Hasty AH; Thompson CB; Wasserman DH
Diabetes; 2013 Jun; 62(6):1888-96. PubMed ID: 23349492
[TBL] [Abstract][Full Text] [Related]
19. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
Zhen DB; Coveler A; Zanon S; Reni M; Chiorean EG
Semin Oncol; 2018 Jun; 45(3):107-115. PubMed ID: 30391013
[TBL] [Abstract][Full Text] [Related]
20. Interstitial Pressure in Pancreatic Ductal Adenocarcinoma Is Dominated by a Gel-Fluid Phase.
DuFort CC; DelGiorno KE; Carlson MA; Osgood RJ; Zhao C; Huang Z; Thompson CB; Connor RJ; Thanos CD; Scott Brockenbrough J; Provenzano PP; Frost GI; Michael Shepard H; Hingorani SR
Biophys J; 2016 May; 110(9):2106-19. PubMed ID: 27166818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
